EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 1st, 2018 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • California
This Exclusive License Agreement, effective on September 11, 2018 (“Effective Date”), by and between FATE THERAPEUTICS, Inc., a Delaware corporation with offices located at 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (“Licensee”), and The J. David Gladstone Institutes, a testamentary trust with offices located at 1650 Owens Street, San Francisco, California 94158 (“Gladstone”). Each of Gladstone and Licensee may be referred to herein individually as a “Party” and jointly as the “Parties.” In consideration of the mutual promises and covenants contained herein, and intending to be legally bound hereby, the Parties hereby agree as follows:
COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • November 1st, 2018 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
* Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.
